Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GV20-0251 + Anti-PD-1 in Advanced Solid Tumors
NCT07623642Phase 2Not yet recruiting
- Sponsor
- GV20 Therapeutics
- Start
- Jun 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
A Phase 2 trial of GV20-0251 in solid tumor, sponsored by GV20 Therapeutics. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
GV20-0251
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07623642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07623642.